Agios Pharmaceuticals reported mixed results Wednesday from a Phase 3 study in sickle cell disease that will likely dim hopes of securing a U.S. approval for its drug.

In the one-year study, 41% of patients treated with the Agios drug, called Pyrukynd, achieved an improvement in hemoglobin levels compared to 3% of participants on a placebo — a result that was statistically significant and achieved one of two primary study goals.

However, Pyrukynd was unable to significantly reduce the rate of sickle-cell related pain crises reported by participants compared to placebo — failing the study’s other primary goal.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page